A new wound sealant designed to protect surgical incisions from infection while minimizing scarring has earned a Breakthrough Technology designation from Premier, a major healthcare improvement company. The designation, effective August 1, 2026, allows hospitals in Premier’s network to access special pricing and terms for BRIJ-SEAL, a hypoallergenic, waterproof sealant that forms a protective barrier over post-operative wounds for up to 14 days.
The sealant uses a proprietary adhesive technology that avoids the cyanoacrylates found in many traditional skin glues, which can cause allergic reactions in some patients. In six clinical studies, the same adhesive platform used in the company’s existing Brijjit device showed no reported allergic reactions. BRIJ-SEAL is breathable and flexible, allowing it to move with the skin during healing while keeping bacteria out. It can be used alone as a replacement for standard tapes, dressings, or liquid adhesives, or combined with Brijjit to also reduce tension on the incision.
Clinical evidence, including a randomized controlled trial, has shown that the incision management platform incorporating Brijjit can reduce wound breakdown by 90 percent and minimize scar area by 38 percent. These results suggest the sealant could improve both healing outcomes and patient satisfaction after surgeries such as breast procedures and orthopedic operations. “Driven by customer feedback, we developed a simpler solution that provides a strong bacterial barrier, minimizes the risk of adhesive-related skin reactions, and can be applied quickly and efficiently,” said Tim Gleeson, CEO of BRIJ Medical, in a statement.
This is the third product from BRIJ Medical to receive a Breakthrough Technology designation from Premier, joining the Brijjit BP-100 and Brijjit BP-75 force-modulating tissue bridges. The company aims to give surgeons a complete toolkit for incision management, from closure through recovery. With the new designation, more hospitals across the United States can now access the sealant under pre-negotiated terms, potentially expanding its use in operating rooms nationwide. The company continues to study the technology, with clinical data available upon request, and hopes to further simplify postoperative care while improving outcomes for patients.